714909-31-6

Upstream product

• 5267-64-1 (R)-2-amino-3-phenylpropanol 
• 909295-44-9 N-[(S)-2-(t-butoxycarbonylamino)-3-phenylpropyl][(R)-2-(t-butoxycarbonylamino)-3-phenylpropyl]amine 
• 909295-45-0 N-[(2R)-2-(tert-butoxycarbonylamino)3-phenylpropyl]-N-[(2S)-2-(tert-butoxycarbonylamino)-3-phenylpropyl]-N-[9-fluorenylmethoxycarbonyl]amine 
• 141595-88-2 (R)-tert-butyl (1-bromo-3-phenylpropan-2-yl)carbamate 
• 185384-16-1 (2R)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropylamine 
• 106454-69-7 N-tert-butoxycarbonyl-D-Phenylalaninol 
• 7535-56-0 N-t-butoxycarbonyl-L-phenylalanine 4-nitrophenyl ester 
• 185384-18-3 [(R)-1-Benzyl-2-((S)-2-tert-butoxycarbonylamino-3-phenyl-propionylamino)-ethyl]-carbamic acid tert-butyl ester 
• 190839-76-0 (2R)-tert-butyl-(2-azidomethyl-1-benzylethyl) carbamate 

Downstream Products

• 909294-75-3 N-[(S)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl][(R)-2-(thiazol-5-ylmethoxycarbonylamino)-3-phenylpropyl]amine 

Relevant academic research and scientific papers

Synthesis and evaluation of inhibitors of cytochrome P450 3A (CYP3A) for pharmacokinetic enhancement of drugs

The HIV protease inhibitor ritonavir (RTV) is also a potent inhibitor of the metabolizing enzyme cytochrome P450 3A (CYP3A) and is clinically useful in HIV therapy in its ability to enhance human plasma levels of other HIV protease inhibitors (PIs). A nov

Novel compounds that are useful for improving pharmacokinetics

Novel compounds of formula 1 or a pharmaceutically acceptable salt thereof inhibit cytochrome P450 monooxygenase.

Synthesis of C2-symmetric (S,S)-1,4-dibenzyl-DTPA and 1,4-meso-dibenzyl-DTPA via chiral diamines

Novel routes to C2-symmetric (S,S)-1,4-dibenzyl-DTPA and 1,4-meso-dibenzyl-DTPA are described. The methodology utilizes readily available starting materials.